Failed studies should not be used to malign good treatments

Journal of Clinical Psychiatry

Volumn 75, Issue 11, 2014, Pages e1328-

  Gerbarg, Patricia L ^a   Muskin, Philip R ^b   Bottiglieri, Teodoro ^c   Brown, Richard P ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b NewYork Presbyterian Hospital   (United States)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; DESIPRAMINE; ESCITALOPRAM; IMIPRAMINE; MINAPRINE; NOMIFENSINE; PLACEBO; S ADENOSYLMETHIONINE; ANTIDEPRESSANT AGENT; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ANTIDEPRESSANT ACTIVITY; DRUG EFFICACY; DRUG RESEARCH; HAMILTON DEPRESSION RATING SCALE; HUMAN; LETTER; MAJOR DEPRESSION; MEDICAL DOCUMENTATION; MEDICAL ERROR; METHODOLOGY; MONOTHERAPY; OUTCOME ASSESSMENT; PATIENT SELECTION; PLACEBO EFFECT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT RESPONSE; VALIDITY; DEPRESSIVE DISORDER, MAJOR; FEMALE; MALE;

ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; MALE; S-ADENOSYLMETHIONINE; SEROTONIN UPTAKE INHIBITORS;

EID: 84927566081     PISSN: 01606689     EISSN: 15552101     Source Type: Journal    
DOI: 10.4088/JCP.14lr09266     Document Type: Letter

References (10)

1. Mischoulon D, Price LH, Carpenter LL, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-l-methionine (SAMe) versus escitalopram in major depressive disorder. J Clin Psychiatry. 2014;75(4):370-376. doi:10.408/JCP.13m08591 PubMed
2. Iovieno N, Papakostas GI. Correlation between different levels of placebo response rate and clinical trial outcome in major depressive disorder: A metaanalysis. J Clin Psychiatry. 2012;73(10):1300-1306. doi:10.408/JCP.1r07485 PubMed
3. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry. 2013;170(7):723-733. doi:10.176/api.ajp.2012.12040474 PubMed
4. US Departments of Health and Human Services Agency for Healthcare Research and Quality (AHRQ). (2002). S-adenosyl-l-methionine for treatment of depression, osteoarthritis, and liver disease. Summary, Evidence Report/Technology Assessment: Number 64. AHRQ Publication No. 02-E033. http://www.ahrq.gov/clinic/epcsums/samesum.htm. Updated August 2002. Accessed October 8, 2007.
5. Bottiglieri T. Folate, vitamin B12, and S-adenosylmethionine. Psychtr Clin North Am. 2013;36(1):1-13. doi:10.1016/j.psc.2012.12.01 PubMed.
6. Brown RP, Gerbarg PL. Herbs and nutrients in the treatment of depression, anxiety, insomnia, migraine, and obesity. J Psychiatr Pract. 2001;7(2):75-91. doi:10.1097/0131746-201030-02 PubMed
7. Brown RP, Gerbarg PL, Bottiglieri T. S-Adenosylmethionine in depression: biochemical and clinical evidence. Psychiatr Ann. 2002;32(1):29-44. doi:10.3928/048-5713-2020101-07
8. Brown RP, Gerbarg PG, Muskin PR. In: Tasman A, Kay J, Lieberman J, eds. Alternative Treatments in Psychiatry in Psychiatry. 3rd ed. Chapter 108. London, UK: John Wiley & Sons; 2008:2318-2353.
9. Brown RP, Gerbarg PL, Muskin PR. How to Use Herbs, Nutrients, and Yoga in Mental Health Care. New York, NY: W W Norton & Company; 2009.
10. Papakostas GI, Shelton RC, Zajecka JM, et al. Effect of adjunctive l-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: results from a randomized clinical trial. J Clin Psychiatry. 2014;75(8):855-863. doi:10.408/JCP.13m08947